Member area login
You don't have or don't remember the password!
Click Here
Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091



Articoli con TAG: valutazione del rischio

Applicazione del Sistema Toyota alla fase pre-analitica come azione di miglioramento a seguito di un evento avverso: l'esperienza del Laboratorio Analisi dell'Istituto Fiorentino di Cura e Assistenza (IFCA)
Pre-Analitycal phase optimization through Lean Principles as a reaction to an adverse event: the experience of the laboratory service of the Istituto Fiorentino di Cura e Assistenza (IFCA)
<p>Introduction: incident reporting and risk analysis are pivotal activities in the clinical laboratory to ensure patient safety. This paper describes an adverse event that occurred in February 2021 in the clinical laboratory of the Istituto Fiorentino Cura e Assistenza (IFCA) relating to a SARS-CoV-2 testing. Briefly, patients need a negative molecular test on a sample taken 2 days pre-operatively, but in one occasion a number of tests were not done on time due to a failure of the laboratory organization, and the surgery was postponed.<br />Methods: the subsequent analysis of the event showed that a rethinking of the entire pre analytical phase was necessary and the Toyota Production System (TPS) was used to establish a completely revised work flow.<br />Results: with the involvement of the entire laboratory staff and the support of a TPS specialist, the pathway was entirely redesigned: tubes colour codes were defined, dedicated working areas were implemented in order to obtain a space where the staff members can verify, at a glance, the status and the results of each step of the workflow.<br />Discussion: the application of the Toyota system to the pre-analytical phase of the laboratory has created a tidy and clean environment, with dedicated spaces for all the samples. The involvement of the staff in the improvement process has guaranteed the compliance of the operators to the new organisation.</p>
Biochimica Clinica ; 17(1)
Contributi Scientifici - Scientific Papers
 
La biologia molecolare clinica nella valutazione e prevenzione del rischio cardiologico nell’attività sportiva e nell’attività motoria intensa
Clinical molecular biology in the assessment and prevention of cardiological risk in case of participation in sports activity and intense physical activity
<p>We review the clinical molecular biology approach for the prevention of cardiological diseases, essentially via risk assessment at personal level by DNA analysis. Intense physical activity, particularly during athletic performances, can result in syncope or even cardiac arrest, often followed by sudden<br />cardiac death. An approach to the prevention of such tragic events is predictive medicine (presence of pathogenic mutations in cardiac genes), besides the conventional tools used in cardiology (mainly electro and echocardiogram under stress conditions). Accordingly, we list the major cardiac diseases and their related genes and derivative proteins which are instrumental for normal heart function. Alterations can occur in ion channel genes, in genes<br />encoding desmosomial and junctional proteins, sarcomeric and Z-disc proteins, proteins for the cytoskeleton at the nuclear envelope, and in genes encoding mitochondrial proteins. Thus, we constructed two sets of gene panels: one set to discriminate among confounding heart diseases, and another set based on a cost-benefit criterion according to the most or less frequent genes bearing pathogenic variants that entail a higher or lower predisposing risk. This<br />approach should be used to monitor pre-participation athletes and also amateurs who belong to families in which at least 1-2 subjects are affected by cardiac alterations. The risk should be identified with the aim to monitor subjects in order to prevent cardiac arrest and even sudden cardiac death.</p>
Biochimica Clinica ; 43(1) 024-043
Rassegne - Review